Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2025
0mins
Source: Businesswire
Appointment of Dr. Raymond Sanchez: Alto Neuroscience has appointed Dr. Raymond Sanchez to its Board of Directors, effective August 12, 2025. Dr. Sanchez brings over 20 years of experience in the life sciences and will support the company's clinical-stage precision psychiatry programs.
Alto's Mission and Pipeline: Alto Neuroscience aims to redefine psychiatry through personalized treatment options by leveraging neurobiology, with a pipeline that includes drug candidates for various mental health conditions such as bipolar depression and schizophrenia.
Analyst Views on ANRO
Wall Street analysts forecast ANRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANRO is 30.71 USD with a low forecast of 15.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.020
Low
15.00
Averages
30.71
High
50.00
Current: 17.020
Low
15.00
Averages
30.71
High
50.00
About ANRO
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
